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Fibrosing cholangiopathy such as primary sclerosing cholangitis
(PSC) and biliary atresia (BA) is characterized by biliary epithelial
injuries and concentric ﬁbrous obliteration of the biliary tree
together with inﬂammatory cell inﬁltration. In these diseases,
inappropriate innate immunity is reported to contribute more
to bile duct pathology as compared with various aspects of ‘‘clas-
sical’’ autoimmune diseases. Primary biliary cirrhosis (PBC) is
characterized by chronic cholangitis with bile duct loss and clas-
sical autoimmune features. Cellular senescence of cholangiocytes
and a senescence-associated secretory phenotype lead to the pro-
duction of proinﬂammatory cytokines and chemokines that may
modify the milieu of the bile duct and then trigger ﬁbroinﬂam-
matory responses in PSC and PBC. Furthermore, deregulated
autophagy might be involved in cholangiocyte senescence and
possibly in the autoimmune process in PBC, and the deregulated
innate immunity against enteric microbes or their products that
is associated with cholangiocyte senescence might result in the
ﬁbrosing cholangitis that develops in PBC and PSC. In BA, innate
immunity against double-stranded RNA viruses might be
involved in cholangiocyte apoptosis and also in the development
of the epithelial-mesenchymal transition of cholangiocytes that
results in ﬁbrous obliteration of bile ducts. These recent advances
in the understanding of immune-mediated biliary diseases repre-
sent a paradigm shift: the cholangiocyte is no longer viewed
merely as a passive victim of injury; it is now also considered
to function as a potential effector in bile duct pathology.Journal of Hepatology 20
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The biliary tree is composed of a ramifying tubular network that
modiﬁes the composition of bile and serves as a conduit for the
delivery of bile to the duodenum [1–4]. The epithelial lining cells
(cholangiocytes) exhibit heterogeneities in their morphologies,
phenotypes and gene expression along the biliary tree and func-
tion as a secretory/absorptive epithelium and other physiological
roles [5–8]. Cholangiopathies are a diverse group of biliary disor-
ders of distinct etiologies, and they include, for example,
immune-mediated, drug-induced and infectious cholangiopa-
thies [1,2,9–12]. Among them, ﬁbrosing cholangiopathies such
as primary sclerosing cholangitis (PSC) and biliary atresia (BA)
are characterized by cholangiocytic injuries and progressive
ﬁbrous obliteration of the biliary tree associated with nonspeciﬁc
inﬂammatory cell inﬁltration [1,2,9–12]. Whereas PSC and BA are
considered complex disorders involving multiple etiopathogenet-
ic factors, immune system-mediated assaults against the cholan-
giocytes are regarded a central feature [1,2,9–16]. Primary biliary
cirrhosis (PBC), another form of ﬁbrosing cholangiopathy [17,18],
is associated with marked lymphoplasmacytic inﬁltration around
the interlobular ducts (chronic nonsuppurative destructive cho-
langitis (CNSDC)) and classical autoimmune features including
disease speciﬁc antimitochondrial antibodies (AMAs) [19].
In response to diverse stresses, cholangiocytes exhibit various
passive and adverse cytopathic changes such as cellular swelling
or shrinkage. This is followed either by the repair or regeneration
of cholangiocytes or by bile duct loss through apoptosis or necro-
sis [2,20]; the pathology and pathogenesis of these processes
have been extensively studied [2,8,20,21]. However, recent stud-
ies have engendered a novel paradigm of the biliary epithelial
pathophysiology: cholangiocytes, which were once considered
to act as a passive victim under pathologic conditions, are now
recognized as active players in the biliary proinﬂammatory
response to various stresses [8,14,21–23].
Herein, we ﬁrst review the general aspects of senescence and
autophagy and the signiﬁcance of cholangiocyte senescence and
autophagy with respect to deregulated innate immunity. We will
then discuss the participation of senescence, deregulated autoph-
agy and inappropriate biliary innate immunity in the bile duct
lesions in PBC and PSC. Lastly, we will discuss the inappropriate15 vol. 62 j 934–945
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Fig. 1. Cellular responses to stress. Apoptosis, autophagy, and cellular senes-
cence are distinct cellular responses to stress. Autophagy is induced in response
to a wide variety of stresses, and there are many purposes for autophagy such as
the quality control of protein and organelle, damage mitigation, and energy
homeostasis. Stressed cells activate autophagy, which prevents damage and
maintains metabolism though lysosomal turnover of cellular components.
Autophagy can facilitate senescence or limit damage and delay apoptosis to
allow recovery and repair of normal cell function (modiﬁed from [12]).
JOURNAL OF HEPATOLOGY
biliary innate immunity with possible roles of cholangiocyte
senescence in BA.
Key Points
• While cellular senescence, autophagy and apoptosis 
are distinct cellular responses to various cellular 
stresses, they are correlated with each other, and cross 
talk and interaction in signaling pathways, particularly 
AKT/mTOR and p53, are often overlapping in deciding 
these responses
• Cellular senescence of cholangiocytes and a 
senescence-associated secretory phenotype lead 
to the production of proinflammatory cytokines and 
chemokines that may modify the milieu of the bile 
duct and then trigger fibroinflammatory responses in 
fibrosing cholangiopathy
• Deregulated autophagy might be involved in 
cholangiocyte senescence and also possibly in the 
autoimmune phenomena such as production of disease 
specific autoantibodies in fibrous cholangiopathy
• In fibrosing cholangiopathies, inappropriate innate 
immunity is reported to contribute to their unique bile 
duct pathology
• In the understanding of fibrosing cholangiopathy, the 
cholangiocyte is no longer viewed merely as a passive 
victim of injury, it is now also considered to function 
as a potential effector in the bile duct pathology
Cellular senescence and autophagy with respect to apoptosis
Cells respond to various stresses by means of adaptation, autoph-
agy, and recovery, or they either commit to irreversible cell-cycle
exit (senescence) or are eliminated through programmed cell
death (apoptosis) [24]. While cellular senescence, autophagy
and apoptosis are distinct cellular responses to stress, they are
correlating with each other, and signaling pathways involved
are often overlapping each other [25–32]. For example, autoph-
agy is considered a survival mechanism when faced with cellular
insults, however extensive autophagy can also lead to senescence
or apoptosis (Fig. 1) [30–36].
Cellular senescence
Senescence is a condition in which a cell can no longer proliferate
and senescent cells are irreversibly arrested at the G1 phase
[25,27,37]. These cells do not respond to various external stimuli,
but they remain metabolically active. Senescence can be trig-
gered by multiple mechanisms, including derepression of the
INK4a/ARF locus, telomere dysfunction, oxidative stress, and
oncogene activation [25–28,38]. In contrast to apoptosis, senes-
cence is typically a delayed stress response that involves multiple
effector mechanisms, and it can serve a program that protects
against cellular insults [39,40]. Senescence is regarded as a mech-
anism responsible for irreversibly blocking the proliferation of
cells that harbor genomic injuries [25,27]. Senescent cells display
several distinctive characteristics such as unique histological
changes [41,42], increased expression of p16INK4 and
p21WAF1/Cip, and increased activity of senescence-associatedJournal of Hepatology 201b-galactosidase (SA-b-gal) [43]. As well as progression to a senes-
cence-associated secretory phenotype (SASP), which is a persis-
tent hypersecretory state characterized by increased expression
and secretion of inﬂammatory molecules such as cytokines, che-
mokines, growth factors and proﬁbrotic factors [5,37,39,44–51].
Autophagy
Autophagy is a genetically regulated program for self-degrada-
tion aimed to remove long-lived or damaged proteins and organ-
elles, and for recycling of cytoplasmic content [40,52,53].
Autophagy maintains cellular viability during periods of various
stresses [30–32,40,52,53]. During cellular stress, autophagy is
activated and organelles are sequestered in autophagosomes
and digested through fusion with lysosomes. Autophagy can act
both as a temporary protective mechanism during a brief stress-
ful episode and the adaptive response of autophagy enables the
cells to maintain homeostasis and to survive starvation stress
[54]. However, depending on the stress or stimuli autophagy also
contributes to cell death, called autophagic cell death [55].
Relations among apoptosis, autophagy and cellular senescence
Recently, autophagy has been identiﬁed as an effector mecha-
nism of senescence [33]. During senescence, autophagy is
induced and activated, consequently facilitating the process of
senescence. Furthermore, inhibition of autophagy delayed the
senescence phenotype [33]. Autophagy is regulated by several
kinases, particularly mTOR and AKT [30,31]. Apoptosis is central
to various physiological processes and the maintenance of
homeostasis [32], its induction eliminates damaged cells medi-
ated through the action of tumor suppressor p53 [32]. However,
in order to prevent excessive loss of injured cells, apoptotic path-
ways are counteracted by anti-apoptotic signaling including the
AKT/mTOR pathway [30–32]. AKT/mTOR not only prevents cell
death, but is active in cell cycle transition, thereby also counter-
acting p53. The balance between p53 and AKT/mTOR determines
the fate of injured cells. AKT/mTOR is tuned down by the negative
regulators being controlled by the p53. This inhibition of AKT/
mTOR, in combination with transactivation of damage-regulated5 vol. 62 j 934–945 935
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autophagy modulators, guides the p53-mediated elimination of
damaged cellular components by autophagic clearance. Alterna-
tively, p53 irreversibly blocks cell cycle progression to prevent
AKT/mTOR-driven proliferation, thereby inducing premature
senescence [30–32]. Under slightly different physiological condi-
tions, concomitant activation of p53 and AKT/mTOR can drive
cells into senescence. Cross talk and interaction between AKT/
mTOR and p53 inﬂuences the cell response deciding over death
or survival [30–32,55,56].Signiﬁcance of cholangiocyte senescence with respect to
deregulated innate immunity
Cholangiocytes are continuously exposed to bile: in addition to
endogenous bile constituents, cholangiocytes can be consistently
exposed to microbes or their products such as lipopolysaccharide
(LPS) that are cleared from portal venous blood by hepatocytes
and are secreted into bile under normal and pathologic condi-
tions [2,4,56]. These substances potentially elicit proinﬂamma-
tory and chemotactic responses. However, cholangiocytes in
healthy livers are tightly regulated in order to prevent the devel-
opment of abnormal responses to such endogenous or exogenous
bile components [56].
Recently, cholangiocytes have been widely reported to func-
tion as active players in the bile duct pathologies in several chol-
angiopathies, including PBC and PSC [8,13,21,22,57–64]. The
cholangiocytes can acquire an activated phenotype and aber-
rantly express various receptors, chemokines, cytokines, and
other growth factors, they can also interact with pathogen-
associated molecular patterns (PAMPs). Speciﬁcally, recent
studies have shown that the deregulation of innate immunity
and the induction of cellular senescence in cholangiocytes are
involved in the pathogenesis of immune-mediated biliary
diseases [8,13,21,22,44,57]. The activation of the Toll-like
receptor (TLR) family upon ligation by PAMPs and the induction
of SASP are respectively reported to trigger the secretion of
proinﬂammatory molecules from the cholangiocytes, and these
might initiate and modulate bile duct pathology [21,45,65].
Cholangiocyte senescence
Cholangiocyte senescence is reported to be involved in the
immune-mediated bile duct pathology [66–68]. For example, in
chronic liver-allograft rejection which is characterized by a pro-
gressive loss of intrahepatic bile ducts [66,69], the expression of
senescence-related p21WAF1/Cip protein is increased in cholangio-
cytes during early chronic rejection [66]. Replicative senescence
accounts for the characteristic cytological alterations of cholan-
giocytes that is used for the diagnosis of early chronic rejection.
Unsuccessful recovery from cholangiocyte senescence might be
responsible for the progressive bile duct loss in chronic allograft
rejection [66].
Cellular senescence and SASP
Senescent cholangiocytes can play a critical role in modulating
the microenvironment by secreting the proinﬂammatory mole-
cules belonging to SASP. Whereas senescence and SASPs contrib-
ute to tissue-repair processes, the persistence of senescent cells
and SASPs might have pathologic consequences such as persis-
tent tissue inﬂammation and impaired tissue integrity, and are936 Journal of Hepatology 201reported to be involved in the pathogenesis of diverse human dis-
eases including biliary diseases [70–72].
Bystander effect
Recent studies [45,49,65] suggest that cytokines/chemokines
produced by senescent cholangiocytes could also facilitate cellu-
lar senescence in bystander cholangiocytes and other types of
cells in the periductal tissue. For example, we have shown that
CCL2 and CX3CL1, which are components of the SASPs of senes-
cent cholangiocytes, induced cellular senescence in cholangio-
cytes [45,49,65]. This effect may lead to the accumulation of
senescent cholangiocytes in the affected ducts and also senescent
mesenchymal cells around the bile ducts in ﬁbrosing
cholangiopathies.
Senescence and phenotypic dedifferentiation of cholangiocytes
Recently, Brain et al. demonstrated a key role of senescence in
acute cellular rejection [69]. Acute liver-allograft sections showed
a positive correlation between increasing grades of acute rejec-
tion and the number of cholangiocytes expressing the senescence
marker p21WAF1/Cip or the mesenchymal marker S100A4. Inter-
estingly, in the in vitro study, oxidative stress induced expression
of the senescent markers transiently in cultured cholangiocytes.
Subsequently, the cholangiocytes exhibited increased expression
of S100A4 coupled with a decrease of epithelial markers. This
dedifferentiation was associated with production of TGF-b2 by
senescent cholangiocytes [69]. They suggested that although some
of the injured cholangiocytes died in acute allograft rejection,
many of them survived in the functionally compromised state of
senescence and phenotypic dedifferentiation that was coupled
with the acquisition of the mesenchymal marker. This might be
related to the epithelial-mesenchymal transition (EMT) of cholan-
giocytes and progressive ﬁbrosis around the bile duct, and could
potentially represent a novel role of senescent cholangiocytes.
Cellular senescence in relation to innate immunity
As described above, proinﬂammatory molecules are secreted by
senescent cholangiocytes and SASPs [37,47,73–76]. Interestingly,
when cultured cholangiocytes are treated with PAMPs, a treat-
ment that reﬂects an activation of innate immunity, the cholan-
giocytes exhibit similar behaviors [77]. Thus, it is of interest to
understand how ‘‘senescence’’ and ‘‘activated innate immunity’’
are related to each other.
Innate immunity
Activation of innate immunity. Members of the TLR family are the
best-characterized cell-surface receptors that recognize PAMPs,
and, in humans, 10 TLRs (TLR1–10) have been identiﬁed
[22,78–80]. In addition to immunocompetent cells, epithelial
cells such as the intestinal epithelia express multiple TLRs. The
activation of TLRs triggers an array of epithelial defense
responses, including the production and release of antimicrobial
peptides and cytokines/chemokines [81].
Biliary innate immunity. Similar to the intestinal mucosa, the bil-
iary mucosa expresses multiple TLRs and intracellular adaptor
molecules (myeloid differentiation factor 88 (MyD88) and recep-
tor-associated kinase-1 (IRAK-1)), and the ligation of the recep-
tors leads to intracellular signaling [8,81]. For example, the
response to LPS is mediated by an interaction with TLR4, which5 vol. 62 j 934–945
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initiates the transduction of intracellular signals and this is fol-
lowed by the activation of MyD88 and IRAK-1, resulting in the
activation of NF-jB and then to the synthesis of antibiotics and
also proinﬂammatory cytokines/chemokines [78,79]. As part of
a host’s defenses, cholangiocytes participate directly and actively
in biliary innate immunity by secreting several antibiotics against
bacteria [76,79] and also proinﬂammatory molecules such as
IL-6, TNF-a, IL-8, CX3CL1, and CCL2 [48,57,80–89]. These chemo-
kines can trigger the recruitment and activation of T cells,
macrophages, neutrophils, and NK cells, followed by persistent
periductal inﬂammation. In contrast to bacterial PAMPs, dou-
ble-stranded RNA (dsRNA) is recognized by TLR3, and this is fol-
lowed by the activation of interferon regulatory factor 3 (IRF-3)
and NF-jB [13]. Collectively, the resultant periductal cytokine
networks that are formed, contribute to biliary mucosal defense,
and also the pathogenesis of ﬁbrous cholangiopathy, and the sub-
sequent acquired immunity [5,22,77,78,84,85]. A signaling path-
way initiated by TLRs also involves activation of Ras,mediating the
production of proinﬂammatory cytokines and chemokines by cho-
langiocytes such as IL6 followed by cholangiocyte proliferation
[90], and also inducing cellular senescence, as described below
[49]. These aspects of biliary innate immunity are shown in Fig. 2.
Correlation between innate immunity and cellular senescence
Recent studies using cultured cholangiocytes showed interesting
ﬁndings connecting innate immunity to oncogene-induced cellu-
lar senescence [9,48,49,90]. N-Ras is the predominant Ras iso-
form expressed in cholangiocytes. The short-term interaction of
TLRs with LPS in cholangiocytes activate N-Ras and this results
in the rapid phosphorylation of the downstream Ras effectors
extracellular signal-regulated kinases (ERKs) 1 and 2 and the
secretion of IL-6 [90]. That is, a signaling pathway initiated byTLR
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Fig. 2. Innate immunity and physiopathological reactions in cholangiocytes. Activat
(TLRs) by pathogen-associated molecular patterns (PAMPs), induce several effector p
secretion of chemokines and cytokines, ii) defense against bacterial and viral infection by
of N-Ras (oncogene-induced senescence), iv) cell proliferation associated with IL-6, v) c
induced by tumor factor-related apoptosis-inducing ligand (TRAIL) (EMT, epithelial-mes
Journal of Hepatology 201TLRs involving Ras mediates the production of proinﬂammatory
cytokines and chemokines by cholangiocytes and the induction
of cholangiocyte proliferation in response to microbial insult [90].
In contrast, persistent LPS treatment of cholangiocytes
induced the expression of mediators of cellular senescence such
as p16INK4a and p21WAF1/Cip in cholangiocytes [49]. After an initial
increase in Ki-67 mRNA expression, as mentioned above, this was
followed by a progressive decrease in proliferation, consistent
with a nonreplicative state. The percentage of SA-b-gal-positive
cholangiocytes increased substantially among cholangiocytes
treated with LPS, indicating an induction of cholangiocyte senes-
cence. SASP components were also strongly induced in these cho-
langiocytes, indicating the progression of senescent cultured
cholangiocytes to a SASP in vitro. Furthermore, N-Ras expression
and activation peaked in LPS-treated cholangiocytes and
remained elevated [49], and this may have induced senescence
(oncogene-induced cellular senescence) [48,49].
Collectively, the aforementioned results revealed that N-Ras is
activated in cholangiocytes following acute and also persistent
LPS treatment. Whereas acute treatment induced the activation
of innate immunity coupled with increased proliferative activi-
ties, persistent treatment triggered cellular senescence (Fig. 2).
In chronic biliary diseases, the persistent process might predom-
inate and the acute process could overlap with it.
Cellular senescence and autophagy in ﬁbrosing
cholangiopathies
While PBC, PSC, and BA belonging to ﬁbrosing cholangiopathy
[17,18] present distinct and unique pathological and immunological
features, they also share common disease processes such as senes-
cence, autophagy and inappropriate biliary innate immunity.PAMPs
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Primary biliary cirrhosis
A high prevalence of vaginal and urinary tract infections and the
presence of bacterial components in bile and liver tissue and the
molecular mimicry of human and bacterial pyruvate dehydroge-
nase complex-E2 (PDC-E2, a major epitope of AMAs), are reported
in PBC [19,56,91–94]. Suggesting that the presence of microbes
and the innate immune responses against them are also involved
in the pathogenesis of PBC in addition to classical autoimmune
features.
Cellular senescence and SASP
Cholangiocyte senescence exhibiting shortened telomeres, SA-b-
gal expression, and augmented expression of p16INK4a and
p21WAF1/Cip were reported frequently in CNSDC (Fig. 3), a which
suggested that senescence might be involved in the formation
of CNSDC and progressive bile duct loss in PBC [44,95]. While cel-
lular senescence can be triggered by a number of stresses, oxida-
tive stress is a potential causative factor in CNSDC in PBC
[21,34,63,96]. For example, p21WAF1/Cip1 and an oxidative stress
marker, 8-OHdG, were frequently and extensively coexpressed
in the nuclei of CNSDC in PBC, and their expressions were corre-
lated [34]. In addition, activation of biliary innate immunity by
PAMPs is known to promote CX3CL1 and CX3CR1 expression in
cholangiocytes followed by the recruitment of intraepithelial
cytotoxic lymphocytes of CNSDC [50], possibly via senescence
as mentioned above [49,76,78,90,94].
Most upregulated cytokines/chemokines in CNSDC are com-
ponents of SASPs [44,45,63,65], and senescent cholangiocytesAutophagosome
Lysosome
Autolysosome
Nucleus
Stress
M
MH
Fig. 3. A hypothesis on the association of deregulated autophagy of cholangiocytes a
the intracellular antigen processing required for the presentation of major histocompatib
and this may be implicated in increased autophagosomes with increased expression
presentation of MHC class I and class II. The cell-surface expression of mitochondrial antig
lead to antigen presentation by MHC class I and II to immunocompetent cells such as d
cytotoxic T cells, followed by autoimmune reactions.
938 Journal of Hepatology 201are involved in modulating the periductal inﬂammatory microen-
vironment in CNSDC [63]. For example, the expression of CCL2
and CX3CL1 was substantially elevated in cholangiocytes in
CNSDC in PBC, and their expression was colocalized with the
expression of senescence markers. CCL2 and CX3CL1 produced
by senescent cholangiocytes might promote inﬁltration by corre-
sponding CCR2- and CX3CR1-expressing mononuclear cells and
further aggravate cholangitis and eventual duct loss [73,97].
These ﬁndings suggest that senescent cholangiocytes may partic-
ipate in modulating, through their SASPs, the inﬂammatory
microenvironment by recruiting monocytes and possibly other
types of inﬂammatory cells.
Progressive bile duct loss and senescence
When cholangiocyte senescence occurs in injured bile ducts,
the cholangiocytes are reported to remain in situ and not be
replaced by normal cholangiocytes [21,44,98,99]. Therefore,
the impaired replacement and nonproliferative properties of
senescent cholangiocytes make them prone to further injuries,
and this accentuates the inﬂammation caused by SASPs and is
eventually followed by bile duct loss. Cellular senescence of
the bile ductules that harbor hepatic stem/progenitor cells
[44] might also lead to impaired regeneration of cholangiocytes
in PBC.
Autophagy and bile duct pathology
Recent studies have further demonstrated that autophagy
is involved in the pathogenesis of hepatobiliary diseases [100–
102].Recycle
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C class II
s autoimmune reaction of primary biliary cirrhosis. Autophagy is implicated in
ility complex (MHC) class I and class II. Recycling of autolysosomes is deregulated,
of p62 and LC3 as well as disordered intracellular antigen processing with the
en such as PDC-E2 and of MHC class I or class II molecules on cholangiocytes could
endritic cells, as well as to a direct target antigen recognition by PDC-E2-speciﬁc
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Autophagy and cholangiocytes. Autophagy was speciﬁcally upreg-
ulated in CNSDC along with senescence in PBC [67,101] (Fig. 2).
Vesicles positive for the autophagy marker, microtubule-associ-
ated protein-light chain 3b (LC3) [103], were observed to accumu-
late in the cytoplasm of damaged bile ducts expressing senescence
markers in PBC [101]; this suggested that autophagy could induce
and facilitate cholangiocyte senescence [24,33–35,44,45,53,65].
Furthermore, the aggregation of p62 was speciﬁcally increased
coupled with the accumulation of LC3-positive vesicles in damaged
bile ducts in PBC [95]; p62 is an adaptor protein involved in the
delivery of ubiquitin-bound cargo to autophagosomes [104]. The
accumulation of p62 reﬂects deregulated autophagy with respect
to insufﬁcient processing of the damaged proteins that are bound
to p62 [104]. Therefore, both the accumulation of LC3-positive ves-
icles and the aggregation of p62 could indicate deregulated autoph-
agy in CNSDC in PBC, and deregulated autophagy might be
involved in the induction of cholangiocyte senescence in several
biliary diseases [67,96,100].
Mitochondrial antigen expression and autophagy in cholangiocytes.
Because mitochondria represent a major target of autophagy,
deregulated autophagy of mitochondria may be involved in the
autoimmune pathogenesis that occurs in PBC. Previously, intense
granular expression of PDC-E2, a mitochondrial protein and
major autoantigen in PBC, was observed in CNSDC in PBC [105].
Interestingly, the granular expression of PDC-E2 was closely
related to or colocalized with the expression of the autophagy
marker LC3. In a cell-culture study, the accumulation of LC3-
expressing puncta colocalized with PDC-E2 was markedly
increased in cultured cholangiocytes exposed to various stresses
and, later, the cell-surface expression of PDC-E2 was also detected.
This suggested that the autophagic vacuoles that accumulate as a
result of deregulated autophagy are responsible for the granular
expression and the subsequent cell-surface expression of PDC-E2
[105], which might be closely related to autoimmune pathogenesis
in PBC. Fig. 3 presents our hypothesis regarding the association of
deregulated autophagy and autoimmune pathogenesis in bile duct
lesions in PBC. Notably, autophagy has been implicated in the
intracellular antigen processing required for the presentation of
the major histocompatibility complex (MHC) class I and class II
[106–108]. Collectively, the cell-surface expression of PDC-E2
and of MHC class I or class II molecules on cholangiocytes could
lead to antigen presentation by MHC class I and II to immunocom-
petent cells, as well as to a direct target antigen recognition by
PDC-E2-speciﬁc cytotoxic T cells [2,24,57,109].
Primary sclerosing cholangitis
The exact pathogenesis of the ﬁbrosing cholangiopathy of PSC,
which is frequently associated with inﬂammatory bowel disease
[9,10], remains unclear. However, in PSC, an inappropriate innate
immune response of the biliary tree directed against enteric
microbes or their products, might be pathogenetically involved
[9,10,12,15,110–117]. However, the intestinal lymphocytes acti-
vated in gut-associated lymphoid tissues can also play key roles
in PSC, in which hepatic expression of MAdCAM-1 and CCL25
may recruit these intestinal lymphocytes to the liver [117–120].
Cellular senescence and SASP
Recently, cholangiocytes of affected bile ducts in PSC were
shown to exhibit senescence phenotypes [48,49]. Tabibian et al.Journal of Hepatology 201demonstrated that the cholangiocytes of PSC livers overexpressed
senescence-associated p16INK4a, and that cultured cholangiocytes
derived from PSC explants expressed senescence markers such as
SA-b-gal [48]. The proliferation rate of the cultured cholangio-
cytes derived from PSC explants was low, which supported the
occurrence of senescence. Moreover, SASP components were
highly expressed in cholangiocytes cultured from PSC explants.
These SASP components are presumed to be involved in the che-
motaxis of inﬂammatory cells around bile ducts. For example, IL-
6 can induce the proliferation of auto-reactive T cells and
enhance immunoglobulin production, and T cells as well as sub-
stantial numbers of B cells are detected in the sclerosing cholan-
gitis of PSC [2,10,12]. Other SASP components such as CCL2 and
CX3CL1 might be involved in the periductal ﬁbrosis of PSC [60].
Furthermore, senescent cholangiocytes may acquire mesenchy-
mal features followed by periductal ﬁbrosis as reported in allo-
graft rejection [69,121]. Collectively, these ﬁndings raise the
possibility that PSC cholangiocytes undergo sustained cellular
senescence, and that SASPs, in turn, might contribute to ﬁbrosing
cholangiopathy in PSC.
As described previously, cholangiocytes in which senescence
is experimentally induced can, in turn, cause senescence in
bystander cholangiocytes and other cells [45,65]. These processes
can lead to the accumulation of senescent cholangiocytes in the
biliary tree and amplify the SASP burden by means of paracrine
signaling in PSC [49]. Furthermore, these senescent cholangio-
cytes may relate to ductopenia in PSC as in PBC.
Biliary innate immunity for induction of cellular senescence as a
possible etiology of PSC
Inappropriate innate immunity and the activation of oncogenes,
particularly N-Ras, might be responsible for the induction of cho-
langiocyte senescence [6,48,49,90]. Activation of TLRs in cultured
cholangiocytes from PSC explant livers by using PAMPs, particu-
larly LPS, can induce senescence [49,90]. The PSC cholangiocytes
showed a reversible increase in the expression of TLRs, particu-
larly TLR4, and an activation of the MyD88/IRAK signaling com-
plex, suggesting an association of excessive innate immune
responses with PSC [112–120]. This endotoxin hyper-responsive-
ness was probably caused by the stimulatory effect exerted by
IFN-c and TNF-a, which are abundantly expressed in PSC livers
and which enhance TLR4-mediated endotoxin signaling in cho-
langiocytes [122]. TNF-a inhibition partly restored protective
innate immune tolerance, which suggested that endogenous
TNF-a secretion contributed to inappropriate endotoxin
responses in cholangiocytes in PSC [4].
As mentioned above, in cell-culture studies, Tabibian et al.
found that cholangiocytes expressing active N-Ras showed an
increased proportion of SA-b-gal-positive cells and increased
secretion of IL-6, suggesting that LPS-induced activation of
N-Ras induces the senescence and SASP [5,49]. Interestingly,
N-Ras and activated Ras were both expressed at substantially
higher levels in cholangiocytes of PSC livers than of control livers
[5,49], which supports a potential role for activated N-Ras signaling
in the induction of the cholangiocyte senescence and SASP of PSC.
Autophagy and cellular senescence
O’Hara et al. reported that lysosomal content was markedly
increased in cultured senescent cholangiocytes after LPS
treatment [90]. Lysosomal increase is recognized to be associated
with autophagy, and thus this phenomenon may indicate the5 vol. 62 j 934–945 939
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participation of autophagy in cholangiocyte senescence [21]. Fur-
thermore, PSC patients frequently present autoantibodies such as
the perinuclear anti-neutrophil cytoplasmic antibody (pANCA)
[114,115]. Interestingly, pANCAs appear to cross-react with b-
tubular isotype 5 and with the bacterial cytoskeletal protein FxsZ,
which is expressed by intestinal ﬂora [116]. Thus, autophagy that
is deregulated with respect to the recycling process used against
microbial pathogens might be related to the occurrence of pAN-
CAs in PSC, as speculated in PBC [21,67,68,100,123].
Autoantibodies against cholangiocytes augment proinﬂammatory
conditions of bile ducts
PSC is considered an autoimmune-disease model based on the
development of autoantibodies such as pANCAs and the selective
destruction of bile ducts coupled with lymphoid cell inﬁltration.
Karrar et al. [124] recently reported that biliary epithelial cell
antibodies (BEC-Abs) were frequently detected in PSC patients,
and that the stimulation of cholangiocytes with PSC IgGs contain-
ing BEC-Abs induced the expression of TLR4, TLR9, and MyD88
and the speciﬁc phosphorylation of ERK1/2 and the transcription
factors ELK-1 and NF-jB. These autoantibodies also induce cho-
langiocytes to produce increased levels of IL-6 and the adhesion
molecule CD44 [125]. When TLR-expressing cholangiocytes are
further stimulated with LPS and CpG DNA, they produce high lev-
els of inﬂammatory cytokines/chemokines which in turn might
lead to the recruitment of T cells, macrophages, and neutrophils.
This raises the possibility that the adaptive immune response
(BEC-Ab) elicited in PSC could facilitate the biliary innate
immune response by inducing TLR expression in cholangiocytes.
This chronic and ampliﬁed activation of cholangiocytes by
BEC-Ab and also PAMPs might lead to persistent bile ductDe-regulated
innate immunity
Senescent
cholangiocytes
Fibrosis Senescence of s
(bystande
Autoimmune: BEC-Ab
Cell injuries: ROS, DNA 
damage, PAMPs
Proteases
MMPs, PAI-1
C
Cytokine
Fig. 4. Possible pathogenesis of ﬁbrosing cholangiopathy of primary sclerosing chol
Cell injuries including enteric microbes or their products (PAMPs) and autoantibody agai
senescence-associated secretory phenotype (SASP) and deregulated innate immunity. S
participate in modulation of the inﬂammatory microenvironment by secreting chemo
recruiting monocytes and possibly other types of inﬂammatory cells, induction of senesc
epithelial-mesenchymal transition (EMT) and ﬁbrosis (PAMPs, pathogen-associated mol
940 Journal of Hepatology 201inﬂammation and the subsequent concentric ﬁbrosing oblitera-
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matory cell inﬁltration [61]. However, the target antigens of these
BEC-Abs remain unknown.
The pathogenesis of ﬁbrosing cholangiopathy of PSC with
respect to senescence and deregulated innate immunity is sche-
matically shown in Fig. 4.
Biliary atresia
BA is characterized by a progressive sclerosing obliteration of
extrahepatic bile ducts, though little is known about its patho-
genesis. Although the autoimmune process might play a role in
BA, particularly after virus clearance [126–128], studies con-
ducted using human materials and a virus-infected rodent model
strongly suggest an association of Reoviridae possessing dsRNA
and the deregulated innate immunity of cholangiocytes in the
development of ﬁbrosing cholangiopathy, particularly at the ini-
tial stage [15,129].
Participation of innate immunity
Tolerance to bacterial PAMPs is critical for maintaining homeo-
stasis in the biliary tree [81,89]. Cholangiocytes possess an innate
immune system consisting of TLRs, including TLR3, which recog-
nize dsRNA. In addition, the cholangiocytes that line the rem-
nants of extrahepatic bile ducts are reported to diffusely
express TLR3 in BA [8,14,122,130]. Interestingly, the innate
immune tolerance of dsRNA tolerance is lacking in the cholangio-
cytes, and a sustained induction of the innate immune response
results in chronic inﬂammation and bile duct destruction in BA
[1,8,16]. Thus, deregulated biliary innate immunity is highlyurrounding  cells
r effects)
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involved in the progressive bile duct ﬁbrosis and inﬂammation
that occur at the beginning stage of the disease.
Enhanced apoptosis, epithelial mesenchymal transition and
periductal ﬁbrosis
Stimulation of cultured cholangiocytes with poly(I:C), an analog
of Reoviridae, induced the activation of NF-jB and IRF-3, fol-
lowed by the production of antiviral IFN-b1, and also enhanced
apoptosis through the production of tumor factor-related apopto-
sis-inducing ligand (TRAIL) [8,14]. In BA, the cholangiocytes lin-
ing the remnants of extrahepatic bile ducts showed an
enhancement of the TRAIL and single-stranded DNA-positive
apoptosis in conjunction with the activation of NF-jB and IRF-
3, which suggested that the continuing apoptosis of cholangio-
cytes leads to biliary obliteration in BA [8,14,78]. Although the
deregulated innate immune response to dsRNA reduced the via-
bility of human cultured cholangiocytes in culture through
TRAIL-mediated apoptosis, the rate of cell death was approxi-
mately 70% [8,14].
The cultured cholangiocytes that evaded apoptosis showed a
gradual loss of the epithelial markers CK19 and E-cadherin, and
increased expression of the mesenchymal marker S100A4 and a
transcription factor essential for EMT, Snail; as a result of
increased susceptibility to TGF-b1 and the production of bFGF,
raised the possibility of the occurrence of EMT in cholangiocytes
[8,14,81]. In fact, mesenchymal markers and Snail were
expressed but CK19 and E-cadherin were not expressed in the
cholangiocytes lining the remnants of extrahepatic bile ducts in
BA, suggesting that these cholangiocytes were undergoing EMT
[14]. However, there have been several reports against EMT in
the liver as a source of myoﬁbroblasts, using lineage tracing stud-
ies [131,132]. The surviving cholangiocytes expressing EMT
markers on the remnants may produce the ﬁbrogenic cytokine
TGFb [133], thus activating periductal ﬁbroblasts followed by
the accumulation of an extracellular matrix and progressive
ﬁbrosis. Collectively, these results suggest that these surviving
cholangiocytes expressing EMT markers may directly or indi-
rectly play a major role in the ﬁbrosing cholangiopathy of BA [8].
Epithelial-mesenchymal transition and autophagy and senescence
As discussed previously in acute allograft rejection, senescent
cholangiocytes might be involved in the cholangiocytes express-
ing EMT markers resulting in ﬁbrosing cholangiopathy in BA.
Recently, cellular senescence markers were frequently detected
in most of the Hering canals and in the interlobular bile ducts
in end-stage BA [134], although the occurrence of BA in extrahe-
patic and large intrahepatic bile ducts, a main target of BA, has
not been examined. Senescence or autophagy has been widely
reported to be associated with developmental and also neoplastic
EMT, and cancer cell invasion induced by the activation of EMT
was recently reported to be associated with deregulated autoph-
agy [134,124,71]. An activation of TGF-b/Smad3-dependent sig-
naling plays a key role in regulating autophagy-induced EMT
[135].Fibrosing cholangiopathies share common disease process(es)
PBC, PSC, BA and other ﬁbrosing cholangiopathies present unique
clinicopathological features [1,2,17,18]. However, these ﬁbrosing
cholangiopathies may share several common disease process(es);Journal of Hepatology 201cellular senescence is frequently induced in cholangiocytes of the
affected bile ducts of PBC and PSC, and the senescent cholangio-
cytes may play an important role in modulating the ductal and
periductal microenvironments by secreting SASPs. Different off/
on switch sequences, periods and types of SASP related to the eti-
ologies and genetic backgrounds speciﬁc to PBC and PSC may be
critical for the development of CNSDC and sclerosing cholangitis,
respectively. The biliary HCO3 umbrella which is protective in
biliary physiology, may similarly be disrupted in PBC, PSC and
other ﬁbrosing cholangiopathies [17,18,136,137]. However, the
mechanism of this disruption could be different among these
diseases; in PBC, impaired anion exchanger and reduced
HCO3 secretion may play a key role, while in PSC, the G-protein-
coupled bile acid receptor 1 involved in cAMP-dependent
modulation of cholangiocellular HCO3 secretion may be affected
[136–141]. Inappropriate innate immunity is reportedly involved
in the bile duct lesions of PBC, PSC and BA [13,49,61,90], though
its processes and effects seem to be different among these dis-
eases. In PBC, upregulated biliary innate immunity may be
involved in the secretion of chemokines/cytokines from cholan-
giocytes followed by the development of CNSDC of interlobular
bile ducts. While in BA, deregulated innate immunity may be
involved in apoptosis of cholangiocytes and in occurrence of cho-
langiocytes with EMT features followed by ﬁbrous obliteration of
extrahepatic bile ducts. Increased senescence-associated hetero-
chromatin foci status and increased copies number of TERC, a
RNA component of telomerase, in PSC patients, may reﬂect the
genetic instability and be involved in cholangiocarcinogenesis
[142] but such processes have not been reported in PBC and BA
in which cholangiocarcinoma is rare.
Collectively, several common disease process(es) may be
underlying the development of bile duct lesions in several ﬁbro-
sing cholangiopathies, but the etiologies and genetic backgrounds
related to these processes could be different along the biliary tree
and the resultant pathologies are considerably different among
these ﬁbrosing cholangiopathies.
However, therapeutic amelioration of either or all of these
common disease processes could prevent the progression of
ﬁbrosing cholangiopathies in these patients. That is, exploitation
of methods to evade cellular senescence and restore deregulated
autophagy and inappropriate biliary innate immunity could be a
promising approach for treating these intractable cholangiopa-
thies. A therapeutic approach to these processes require a clear
understanding of its regulation, particularly the signaling related
to ATK/mTOR and p53 which are implicated in the process of
senescence, autophagy and apoptosis [30–32,54,55,143,144].
Furthermore, challenges to detect differences and similarities of
the disease processes in these ﬁbrosing cholangiopathies are also
informative in the evaluation of their unique pathogenesis.Conclusions
PBC, PSC, and BA belonging to ﬁbrous cholangiopathies, present
unique and different clinicopathological features, but they share
several common disease processes. Cholangiocyte senescence is
regarded as one of the key pathogenetic processes of PBC and
PSC. SASPs may modify the milieu of the bile duct with character-
istic cholangiopathies of PBC and PSC. Autophagy may be related
to the cholangiocyte senescence and to the production of disease
speciﬁc autoantibodies in PBC. Deregulated innate immunity5 vol. 62 j 934–945 941
Review
elicited through the activation of N-Ras is involved in inducing
cholangiocyte senescence, followed by the development of scle-
rosing cholangitis in PSC. In BA, deregulated innate immunity
to dsRNA viruses induces cholangiocyte apoptosis and also
EMT, followed by ﬁbrosing biliary obliteration.Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.Authors’ contributions
YN wrote ﬁrst this review paper, and then MS and KH checked
this review paper. We discussed repeatedly and the manuscript
was ﬁnalized.
References
[1] Lazaridis KN, Strazzabosco M, Larusso NF. The cholangiopathies: disorders
of biliary epithelia. Gastroenterology 2004;127:1565–1577.
[2] Nakanuma Y, Zen Y, Portman BC. Diseases of the bile duct. In: Burt BC,
Ferrell LD, editors. MacSween’s pathology of the liver. Freiburg, London,
New York, Oxford, Philadelphia, St Louis, Sydney, Toronto: Churchill
Livingstone; 2012. p. 491–562.
[3] Nakanuma Y, Harada K, Sasaki M, Sato Y. Proposal of a new disease concept
‘‘biliary diseases with pancreatic counterparts’’. Anatomical and patholog-
ical bases. Histol Histopathol 2014;29:1–10.
[4] LaRusso NF, Shneider BL, Black D, Gores GJ, James SP, Doo E, et al. Primary
sclerosing cholangitis: summary of a workshop. Hepatology 2006;44:
746–764.
[5] O’Hara SP, Tabibian JH, Splinter PL, LaRusso NF. The dynamic biliary
epithelia: molecules, pathways, and disease. J Hepatol 2013;58:575–582.
[6] Marzioni M, Glaser SS, Francis H, Phinizy JL, LeSage G, Alpini G. Functional
heterogeneity of cholangiocytes. Semin Liver Dis 2002;22:227–240.
[7] Kullak-Ublick GA, Beuers U, Paumgartner G. Hepatobiliary transport. J
Hepatol 2000;32:3–18.
[8] Harada K, Nakanuma Y. Cholangiopathy with respect to biliary innate
immunity. Int J Hepatol 2012;2012:793569. http://dx.doi.org/10.1155/
2012/793569.
[9] Tabibian JH, O’Hara SP, Lindor KD. Primary sclerosing cholangitis and the
microbiota: current knowledge and perspectives on etiopathogenesis and
emerging therapies. Scand J Gastroenterol 2014;49:901–908.
[10] Aron JH, Bowlus CL. The immunobiology of primary sclerosing cholangitis.
Semin Immunopathol 2009;31:383–397.
[11] Nakanuma Y, Harada K, Sato Y, Ikeda H. Recent progress in the etiopatho-
genesis of pediatric biliary disease, particularly Caroli’s disease with
congenital hepatic ﬁbrosis and biliary atresia. Histol Histopathol 2010;25:
223–235.
[12] Nakanuma Y, Harada K, Katayanagi K, Tsuneyama K, Sasaki M. Deﬁnition
and pathology of primary sclerosing cholangitis. J Hepatobiliary Pancreat
Surg 1999;6:333–342.
[13] Harada K, Sato Y, Itatsu K, Isse K, Ikeda H, Yasoshima M, et al. Innate
immune response to double-stranded RNA in biliary epithelial cells is
associated with the pathogenesis of biliary atresia. Hepatology 2007;46:
1146–1154.
[14] Harada K, Sato Y, Ikeda H, Isse K, Ozaki S, Enomae M, et al. Epithelial-
mesenchymal transition induced by biliary innate immunity contributes to
the sclerosing cholangiopathy of biliary atresia. J Pathol 2009;217:
654–664.
[15] Szavay PO, Leonhardt J, Czech-Schmidt G, Petersen C. The role of reovirus
type 3 infection in an established murine model for biliary atresia. Eur J
Pediatr Surg 2002;12:48–250.
[16] Feldman AG, Mack CL. Biliary atresia: cellular dynamics and immune
dysregulation. Semin Pediatr Surg 2012;21:192–200.
[17] Beuers U, Hohenester S, de Buy Wenniger LJ, Kremer AE, Jansen PL, Elferink
RP. The biliary HCO(3)() umbrella: a unifying hypothesis on pathogenetic942 Journal of Hepatology 201and therapeutic aspects of ﬁbrosing cholangiopathies. Hepatology
2010;52:1489–1496.
[18] EASL Clinical Practice Guidelines. Management of cholestatic liver diseases.
J Hepatol 2009;51:237–267.
[19] Hirschﬁeld GM, Gershwin ME. The immunobiology and pathophysiology of
primary biliary cirrhosis. Annu Rev Pathol 2013;8:303–330.
[20] Harada K, Ozaki S, Gershwin ME, Nakanuma Y. Enhanced apoptosis relates
to bile duct loss in primary biliary cirrhosis. Hepatology 1997;26:1399–1405.
[21] Sasaki M, Nakanuma Y. Biliary epithelial apoptosis, autophagy, and
senescence in primary biliary cirrhosis. Hepat Res Treat
2010;2010:205128. http://dx.doi.org/10.1155/2010/205128.
[22] Harada K, Isse K, Kamihira T, Shimoda S, Nakanuma Y. Th1 cytokine-
induced downregulation of PPARc in human biliary cells relates to
cholangitis in primary biliary cirrhosis. Hepatology 2005;41:1329–1338.
[23] Yasoshima M, Tsuneyama K, Harada K, Sasaki M, Gershwin ME, Nakanuma
Y. Immunohistochemical analysis of cell-matrix adhesion molecules and
their ligands in the portal tracts of primary biliary cirrhosis. J Pathol
2000;190:93–99.
[24] White E, Low SW. Eating to exit: autophagy-enabled senescence revealed.
Genes Dev 2009;23:784–787.
[25] Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging.
Cell 2007;130:223–233.
[26] Iwasa H, Han J, Ishikawa F. Mitogen-activated protein kinase p38 deﬁnes
the common senescence-signalling pathway. Genes Cells 2003;8:131–144.
[27] Gitenay D, Lallet-Daher H, Bernard D. Caspase-2 regulates oncogene-
induced senescence. Oncotarget 2014;5:5845–5847.
[28] de Graaf EL, Kaplon J, Zhou H, Heck AJ, Peeper DS, Altelaar AF. Phospho-
proteome dynamics in onset and maintenance of oncogene-induced
senescence. Mol Cell Proteomics 2014;13:2089–2100.
[29] Zhu B, Ferry CH, Markell LK, Blazanin N, Glick AB, Gonzalez FJ, et al. The
nuclear receptor peroxisome proliferator-activated receptor-b/d (PPARb/d)
promotes oncogene-induced cellular senescence through repression of
endoplasmic reticulum stress. J Biol Chem 2014;289:20102–20119.
[30] Strozyk E, Kulms D. The role of AKT/mTOR pathway in stress response to
UV-irradiation: implication in skin carcinogenesis by regulation of apop-
tosis, autophagy and senescence. Int J Mol Sci 2013;14:15260–15285.
[31] Kalimuthu S, Se-Kwon K. Cell survival and apoptosis signaling as thera-
peutic target for cancer: marine bioactive compounds. Int J Mol Sci
2013;14:2334–2354.
[32] Lockshin RA, Zakeri Z. Cell death in health and disease. J Cell Mol Med
2007;11:1214–1224.
[33] Young AR, Narita M, Ferreira M, Kirschner K, Sadaie M, Darot JF, et al.
Autophagy mediates the mitotic senescence transition. Genes Dev
2009;23:798–803.
[34] Sasaki M, Ikeda H, Nakanuma Y. Activation of ATM signaling pathway is
involved in oxidative stress-induced expression of mito-inhibitory p21WAF1/
Cip1 in chronic non- suppurative destructive cholangitis in primary biliary
cirrhosis: an immunohistochemical study. J Autoimmun 2008;31:73–78.
[35] Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging.
Cell 2007;130:223–233.
[36] Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell
2007;14:739–745.
[37] Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence.
Genes Dev 2010;24:2463–2479.
[38] d’Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von
Zglinicki T, et al. A DNA damage checkpoint response in telomere-initiated
senescence. Nature 2003;426:194–198.
[39] Lawless C, Wang C, Jurk D, Merz A, Zglinicki TV, Passos JF. Quantitative
assessment of markers for cell senescence. Exp Gerontol 2010;45:772–778.
[40] Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell
2008;132:27–42.
[41] Sigal SH, Rajvanshi P, Gorla GR, Sokhi RP, Saxena R, Gebhard Jr DR, et al.
Partial hepatectomy-induced polyploidy attenuates hepatocyte replication
and activates cell aging events. Am J Physiol 1999;276:G1260–G1272.
[42] Brodsky WY, Uryvaeva IV. Cell polyploidy: its relation to tissue growth and
function. Int Rev Cytol 1977;50:275–332.
[43] Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker
that identiﬁes senescent human cells in culture and in aging skin in vivo.
Proc Natl Acad Sci U S A 1995;92:9363–9367.
[44] Sasaki M, Ikeda H, Haga H, Manabe T, Nakanuma Y. Frequent cellular
senescence in small bile ducts in primary biliary cirrhosis: a possible role in
bile duct loss. J Pathol 2005;205:451–459.
[45] Sasaki M, Miyakoshi M, Sato Y, Nakanuma Y. Modulation of the microen-
vironment by senescent biliary epithelial cells may be involved in the
pathogenesis of primary biliary cirrhosis. J Hepatol 2010;53:318–325.5 vol. 62 j 934–945
JOURNAL OF HEPATOLOGY
[46] Coppé JP, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, et al. Senescence-
associated secretory phenotypes reveal cell-nonautonomous functions of
oncogenic RAS and the p53 tumor suppressor. PLoS Biol
2008;2:2853–2868.
[47] Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. Oncogenic BRAF
induces senescence and apoptosis through pathways mediated by the
secreted protein IGFBP7. Cell 2008;132:363–374.
[48] Tabibian JH, Trussoni CE, O’Hara SP, Splinter PL, Heimbach JK, LaRusso NF.
Characterization of cultured cholangiocytes isolated from livers of
patients with primary sclerosing cholangitis. Lab Invest
2014;94:1126–1133.
[49] Tabibian JH, O’Hara SP, Splinter PL, Trussoni CE, LaRusso NF. Cholangiocyte
senescence by way of N-ras activation is a characteristic of primary
sclerosing cholangitis. Hepatology 2014;59:2263–2275.
[50] Acosta JC, O’Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, et al.
Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell
2008;133:1006–1018.
[51] Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ,
et al. Oncogene-induced senescence relayed by an interleukin-dependent
inﬂammatory network. Cell 2008;133:1019–1031.
[52] Mizushima N. Autophagy: process and function. Genes Dev
2007;21:2861–2873.
[53] Yin XM, Ding WX, Gao W. Autophagy in the liver. Hepatology
2008;47:1773–1785.
[54] Kroemer G, Mariño G, Levine B. Autophagy and the integrated stress
response. Mol Cell 2010;40:280–293.
[55] Amelio I, Melino G, Knight RA. Cell death pathology: cross-talk with
autophagy and its clinical implications. Biochem Biophys Res Commun
2011;414:277–281.
[56] Hiramatsu K, Harada K, Tsuneyama K, Sasaki M, Fujita S, Hashimoto T, et al.
Ampliﬁcation and sequence analysis of partial bacterial 16S ribosomal RNA
gene in gallbladder bile from patients with primary biliary cirrhosis. J
Hepatol 2000;33:9–18.
[57] Isse K, Harada K, Zen Y, Kamihira T, Shimoda S, Harada M, et al. Fractalkine
and CX3CR1 are involved in the recruitment of intraepithelial lymphocytes
of intrahepatic bile ducts. Hepatology 2005;41:506–516.
[58] Harada K, Isse K, Sato Y, Ozaki S, Nakanuma Y. Endotoxin tolerance in
human intrahepatic biliary epithelial cells is induced by upregulation of
IRAK-M. Liver Int 2006;26:935–942.
[59] Harada K, Shimoda S, Ikeda H, Chiba M, Hsu M, Sato Y, et al. Signiﬁcance of
periductal Langerhans cells and biliary epithelial cell-derived macrophage
inﬂammatory protein-3a in the pathogenesis of primary biliary cirrhosis.
Liver Int 2011;31:245–253.
[60] Shimoda S, Harada K, Niiro H, Shirabe K, Taketomi A, Maehara Y, et al.
Interaction between Toll-like receptors and natural killer cells in the
destruction of bile ducts in primary biliary cirrhosis. Hepatology
2011;53:1270–1281.
[61] Harada K, Chiba M, Okamura A, Hsu M, Sato Y, Igarashi S, et al. Monocyte
chemoattractant protein-1 derived from biliary innate immunity contrib-
utes to hepatic ﬁbrogenesis. J Clin Pathol 2011;64:660–665.
[62] Ikeda H, Sasaki M, Ishikawa A, Sato Y, Harada K, Zen Y, et al. Interaction of
Toll-like receptors with bacterial components induces expression of CDX2
and MUC2 in rat biliary epithelium in vivo and in culture. Lab Invest
2007;87:559–571.
[63] Sasaki M, Ikeda H, Sato Y, Nakanuma Y. Proinﬂammatory cytokine-induced
cellular senescence of biliary epithelial cells is mediated via oxidative stress
and activation of ATM pathway: a culture study. Free Radic Res
2008;42:625–632.
[64] Mizushima N, Levine B, Klionsky DJ. Autophagy ﬁghts disease through
cellular self-digestion. Nature 2008;451:1069–1075.
[65] Sasaki M, Nakanuma Y. Novel approach to bile duct damage in primary
biliary cirrhosis: participation of cellular senescence and autophagy. Int J
Hepatol 2012;2012:452143. http://dx.doi.org/10.1155/2012/452143.
[66] Lunz III JG, Contrucci S, Ruppert K, Ruppert K, Murase N, Fung JJ, et al.
Replicative senescence of biliary epithelial cells precedes bile duct loss
in chronic liver allograft rejection: increased expression of p21WAF1/Cip1
as a disease marker and the inﬂuence of immunosuppressive drugs. Am J
Pathol 2001;158:1379–1390.
[67] Sasaki M, Miyakoshi M, Sato Y, Nakanuma Y. Autophagy may precede
cellular senescence of bile ductular cells in ductular reaction in primary
biliary cirrhosis. Dig Dis Sci 2012;57:660–666.
[68] Sasaki M, Miyakoshi M, Sato Y, Nakanuma Y. A possible involvement of
p62/sequestosome-1 in the process of biliary epithelial autophagy and
senescence in primary biliary cirrhosis. Liver Int 2012;32:487–499.Journal of Hepatology 201[69] Brain JG, Robertson H, Thompson E, Humphreys EH, Gardner A, Booth TA,
et al. Biliary epithelial senescence and plasticity in acute cellular rejection.
Am J Transplant 2013;13:1688–1702.
[70] Paradis V, Youssef N, Dargère D, Bâ N, Bonvoust F, Deschatrette J, et al.
Replicative senescence in normal liver, chronic hepatitis C, and hepatocel-
lular carcinomas. Hum Pathol 2001;32:327–332.
[71] Chilosi M, Carloni A, Rossi A, Poletti V. Premature lung aging and cellular
senescence in the pathogenesis of idiopathic pulmonary ﬁbrosis and COPD/
emphysema. Transl Res 2013;162:156–173.
[72] Kumar M, Seeger W, Voswinckel R. Senescence-associated secretory
phenotype and its possible role in chronic obstructive pulmonary disease.
Am J Respir Cell Mol Biol 2014;51:323–333.
[73] Sasaki M, Miyakoshi M, Sato Y, Nakanuma Y. Chemokine-chemokine
receptor CCL2-CCR2 and CX3CL1-CX3CR1 axis may play a role in the
aggravated inﬂammation in primary biliary cirrhosis. Dig Dis Sci
2014;59:358–364.
[74] Shimoda S, Harada K, Niiro H, Yoshizumi T, Soejima Y, Taketomi A, et al.
Biliary epithelial cells and primary biliary cirrhosis: the role of liver-
inﬁltrating mononuclear cells. Hepatology 2008;47:958–965.
[75] Tsuneyama K, Harada K, Yasoshima M, Hiramatsu K, Mackay CR, Mackay IR,
et al. Monocyte chemotactic protein-1, -2, and -3 are distinctively
expressed in portal tracts and granulomata in primary biliary cirrhosis:
implications for pathogenesis. J Pathol 2001;193:102–109.
[76] Yasoshima M, Kono N, Sugawara H, Katayanagi K, Harada K, Nakanuma Y.
Increased expression of interleukin-6 and tumor necrosis factor-a in
pathologic biliary epithelial cells: in situ and culture study. Lab Invest
1998;78:89–100.
[77] Harada K, Ohba K, Ozaki S, Isse K, Hirayama T, Wada A, et al. Peptide
antibiotic human beta-defensin-1 and -2 contribute to antimicrobial
defense of the intrahepatic biliary tree. Hepatology 2004;404:925–932.
[78] Harada K, Ohira S, Isse K, Ozaki S, Zen Y, Sato Y, et al. Lipopolysaccharide
activates nuclear factor-kappaB through toll-like receptors and related
molecules in cultured biliary epithelial cells. Lab Invest
2003;83:1657–1667.
[79] Anderson KVA. Toll signaling pathways in the innate immune response.
Curr Opin Immunol 2000;12:13–19.
[80] Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol
2005;17:1–14.
[81] Harada K, Nakanuma Y. Innate immunity in the pathogenesis of cholan-
giopathy: a recent update. Inﬂamm Allergy Drug Targets 2012;11:478–483.
[82] Bals R, Wang X, Wu Z, Freeman T, Bafna V, Zasloff M, et al. Human b-
defensin 2 is a salt- sensitive peptide antibiotic expressed in human lung. J
Clin Invest 1998;102:874–880.
[83] Matsumoto K, Fujii H, Michalopoulos G, Fung JJ, Demetris AJ. Human biliary
epithelial cells secrete and respond to cytokines and hepatocyte growth
factors in vitro: interleukin-6, hepatocyte growth factor and epidermal
growth factor promote DNA synthesis in vitro. Hepatology
1994;20:376–382.
[84] Chen XM, O’Hara SP, Nelson JB, Splinter PL, Small AJ, Tietz PS, et al. Multiple
TLRs are expressed in human cholangiocytes and mediate host epithelial
defense responses to Cryptosporidium parvum via activation of NF-jB. J
Immunol 2005;175:7447–7456.
[85] Harada K, Isse K, Nakanuma Y. Interferon c accelerates NF-jB activation of
biliary epithelial cells induced by Toll-like receptor and ligand interaction. J
Clin Pathol 2006;59:184–190.
[86] Shimoda S, Harada K, Niiro H, Shirabe K, Taketomi A, Maehara Y, et al.
CX3CL1 (fractalkine): a signpost for biliary inﬂammation in primary biliary
cirrhosis. Hepatology 2010;51:567–575.
[87] Okamura A, Harada K, Nio M, Nakanuma Y. Participation of natural killer
cells in the pathogenesis of bile duct lesions in biliary atresia. J Clin Pathol
2013;66:99–108.
[88] Okamura A, Harada K, Nio M, Nakanuma Y. Interleukin-32 production
associated with biliary innate immunity and proinﬂammatory cytokines
contributes to the pathogenesis of cholangitis in biliary atresia. Clin Exp
Immunol 2013;173:268–275.
[89] Harada K, Nakanuma Y. Biliary innate immunity: function and modulation.
Mediators Inﬂamm 2010;2010. http://dx.doi.org/10.1155/2010/373878,
pii: 373878.
[90] O’Hara SP, Splinter PL, Trussoni CE, Gajdos GB, Lineswala PN, LaRusso NF.
Cholangiocyte N-Ras protein mediates lipopolysaccharide-induced inter-
leukin 6 secretion and proliferation. J Biol Chem 2011;286:30352–30360.
[91] Sasatomi K, Noguchi K, Sakisaka S, Sata M, Tanikawa K. Abnormal
accumulation of endotoxin in biliary epithelial cells in primary biliary
cirrhosis and primary sclerosing cholangitis. J Hepatol 1998;29:409–416.5 vol. 62 j 934–945 943
Review
[92] Harada K, Tsuneyama K, Sudo Y, Masuda S, Nakanuma Y. Molecular
identiﬁcation of bacterial 16S ribosomal RNA gene in liver tissue of primary
biliary cirrhosis: is Propionibacterium acnes involved in granuloma forma-
tion? Hepatology 2001;33:530–536.
[93] Parikh-Patel A, Gold EB, Worman H, Krivy KE, Gershwin ME. Risk factors for
primary biliary cirrhosis in a cohort of patients from the United States.
Hepatology 2001;33:16–21.
[94] Harada K, Shimoda S, Sato Y, Isse K, Ikeda H, Nakanuma Y. Periductal
interleukin-17 production in association with biliary innate immunity
contributes to the pathogenesis of cholangiopathy in primary biliary
cirrhosis. Clin Exp Immunol 2009;157:261–262.
[95] Sasaki M, Ikeda H, Yamaguchi J, Nakada S, Nakanuma Y. Telomere
shortening in the damaged small bile ducts in primary biliary cirrhosis
reﬂects ongoing cellular senescence. Hepatology 2008;48:186–195.
[96] Sasaki M, Ikeda H, Sato Y, Nakanuma Y. Decreased expression of Bmi1 is
closely associated with cellular senes-cence in small bile ducts in primary
biliary cirrhosis. Am J Pathol 2006;169:831–845.
[97] Sasaki M, Kakuda Y, Miyakoshi M, Sato Y, Nakanuma Y. Inﬁltration of
inﬂammatory cells expressing mitochondrial proteins around bile ducts
and in biliary epithelial layer may be involved in the pathogenesis in
primary biliary cirrhosis. J Clin Pathol 2014;67:470–476.
[98] Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, et al. Senescence-
associated secretory phenotypes reveal cell-nonautonomous functions of
oncogenic RAS and the p53 tumor suppressor. PLoS Biol
2008;6:2853–2868.
[99] Shelton DN, Chang E, Whittier PS, Choi D, Funk WD. Microarray analysis of
replicative senescence. Curr Biol 1999;9:939–945.
[100] Sasaki M, Miyakoshi M, Sato Y, Nakanuma Y. Increased expression of
mitochondrial proteins associated with autophagy in biliary epithelial
lesions in primary biliary cirrhosis. Liver Int 2013;33:312–320.
[101] Sasaki M, Miyakoshi M, Sato Y, Nakanuma Y. Autophagy mediates the
process of cellular senescence char-acterizing bile duct damages in primary
biliary cirrhosis. Lab Invest 2010;90:835–843.
[102] Teckman JH, An JK, Blomenkamp K, Schmidt B, Perlmuter D. Mitochondrial
autophagy and injury in the liver in alpha 1-antitrypsin deﬁciency. Am J
Physiol Gastrointest Liver Physiol 2004;286:G851–G862.
[103] Saitoh T, Akira S. Regulation of innate immune responses by autophagy-
related proteins. J Cell Biol 2010;189:925–935.
[104] Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y,
et al. The selective autophagy substrate p62 activates the stress responsive
transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol
2010;12:213–223.
[105] Sasaki M, Miyakoshi M, Sato Y, Nakanuma Y. Increased expression of
mitochondrial proteins associated with autophagy in biliary epithelial
lesions in primary biliary cirrhosis. Liver Int 2013;3:312–320.
[106] Nedjic J, Aichinger M, Emmerich J, Mizushima N, Klein L. Autophagy in
thymic epithelium shapes the T-cell repertoire and is essential for
tolerance. Nature 2008;455:396–400.
[107] Paludan C, Schmid D, Landthaler M, Vockerodt M, Kube D, Tuschl T, et al.
Endogenous MHC class II processing of a viral nuclear antigen after
autophagy. Science 2005;307:593–596.
[108] Munz C. Antigen processing via autophagy–not only for MHC class II
presentation anymore? Curr Opin Immunol 2010;22:89–93.
[109] Nakanuma Y, Tsuneyama K, Kono N, Hoso M, Van de Water J, Gershwin ME.
Biliary epithelial expression of pyruvate dehydrogenase complex in
primary biliary cirrhosis: an immunohistochemical and immunoelectron
microscopic study. Hum Pathol 1995;26:92–98.
[110] Matsushita H, Miyake Y, Takaki A, Yasunaka T, Koike K, Ikeda F, et al. TLR4,
TLR9, and NLRP3 in biliary epithelial cells of primary sclerosing cholangitis:
relationship with clinical characteristics. J Gastroenterol Hepatol 2014, in
press.
[111] O’Mahony CA, Vierling JM. Etiopathogenesis of primary sclerosing cholan-
gitis. Semin Liver Dis 2006;26:3–21.
[112] Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of
primary sclerosing cholangitis and advances in diagnosis and management.
Gastroenterology 2013;145:521–536.
[113] Broomé U, Grunewald J, Scheynius A, Olerup O, Hultcrantz R, et al.
Preferential V beta3 usage by hepatic T lymphocytes in patients with
primary sclerosing cholangitis. J Hepatol 1997;26:527–534.
[114] Schwarze C, Terjung B, Lilienweiss P, Beuers U, Herzog V, Sauerbruch T,
et al. IgA class antineutrophil cytoplasmic antibodies in primary sclerosing
cholangitis and autoimmune hepatitis. Clin Exp Immunol
2003;133:283–289.944 Journal of Hepatology 201[115] Pokorny CS, Norton ID, McCaughan GW. Selby WS Anti-neutrophil
cytoplasmic antibody: a prognostic indicator in primary sclerosing cho-
langitis. J Gastroenterol Hepatol 1994;9:40–44.
[116] Terjung B, Söhne J, Lechtenberg B, Gottwein J, Muennich M, Herzog V, et al.
P-ANCAs in autoimmune liver disorders recognise human beta-tubulin
isotype 5 and cross-react with microbial protein FtsZ. Gut
2010;59:808–816.
[117] Eksteen B, Grant AJ, Miles A, Curbishley SM, Lalor PF, Hübscher SG, et al.
Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing
lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med
2004;200:1511–1517.
[118] Seidel D, Eickmeier I, Kühl AA, Hamann A, Loddenkemper C, Schott E. CD8 T
cells primed in the gut-associated lymphoid tissue induce immune-
mediated cholangitis in mice. Hepatology 2014;59:601–611.
[119] Trivedi PJ, Adams DH. Mucosal immunity in liver autoimmunity: a
comprehensive review. J Autoimmun 2013;46:97–111.
[120] Bowlus CL. Cutting edge issues in primary sclerosing cholangitis. Clin Rev
Allergy Immunol 2011;41:139–150.
[121] Rygiel KA, Robertson H, Marshall HL, Pekalski M, Zhao L, Booth TA, et al.
Epithelial-mesenchymal transition contributes to portal tract ﬁbrogenesis
during human chronic liver disease. Lab Invest 2008;88:112–123.
[122] Mueller T, Beutler C, Picó AH, Shibolet O, Pratt DS, Pascher A, et al.
Enhanced innate immune responsiveness and intolerance to intestinal
endotoxins in human biliary epithelial cells contributes to chronic cholan-
gitis. Liver Int 2011;31:1574–1588.
[123] Bansi DS, Fleming KA, Chapman RW. Importance of antineutrophil
cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative
colitis: prevalence, titre, and IgG subclass. Gut 1996;38:384–389.
[124] Karrar A, Broomé U, Södergren T, Jaksch M, Bergquist A, Björnstedt M, et al.
Biliary epithelial cell antibodies link adaptive and innate immune
responses in primary sclerosing cholangitis. Gastroenterology
2007;132:1504–1514.
[125] Xu B, Broome U, Ericzon BG, Sumitran-Holgersson S. High frequency of
autoantibodies in patients with primary sclerosing cholangitis that bind
biliary epithelial cells and induce expression of CD44 and production of
interleukin 6. Gut 2002;51:120–127.
[126] Mack CL, Falta MT, Sullivan AK, Karrer F, Sokol RJ, Freed BM, et al.
Oligoclonal expansions of CD4+ and CD8+ T-cells in the target organ of
patients with biliary atresia. Gastroenterology 2007;133:278–287.
[127] Selmi C, Vergani D, Mieli-Vergani G. Viruses and autoantibodies in biliary
atresia. Gastroenterology 2010;139:1461–1464.
[128] Glaser SS. Biliary atresia: is lack of innate immune response tolerance key
to pathogenesis? Liver Int 2008;28:587–588.
[129] Harada K, Sato Y, Isse K, Ikeda H, Nakanuma Y. Induction of innate immune
response and absence of subsequent tolerance to dsRNA in biliary
epithelial cells relate to the pathogenesis of biliary atresia. Liver Int
2008;28:614–621.
[130] Chuang JH, Chou MH, Wu CL, Du YY. Implication of innate immunity in the
pathogenesis of biliary atresia. Chang Gung Med J 2006;29:240–250.
[131] Kisseleva T, Brenner DA. Is it the end of the line for the EMT? Hepatology
2011;53:1433–1435.
[132] Chu AS, Diaz R, Hui JJ, Yanger K, Zong Y, Alpini G, et al. Lineage tracing
demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal
transition in murine models of hepatic ﬁbrosis. Hepatology
2011;53:1685–1695.
[133] Patsenker E, Popov Y, Stickel F, Jonczyk A, Goodman SL, Schuppan D.
Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming
growth factor-beta activation and retards biliary ﬁbrosis progression.
Gastroenterology 2008;135:660–670.
[134] Gutierrez-Reyes G, del Carmen Garcia de Leon M, Varela-Fascinetto G,
Valencia P, Pérez Tamayo R, Rosado CG, et al. Cellular senescence in livers
from children with end stage liver disease. PLoS One 2010;5:e10231.
[135] Nitta T, Sato Y, Ren XS, Harada K, Sasaki M, Hirano S, et al. Autophagy may
promote carcinoma cell invasion and correlate with poor prognosis in
cholangiocarcinoma. Int J Clin Exp Pathol 2014;7:4913–4921.
[136] Beuers U, Oude-Elferink RP. New light on anion exchangers in primary
biliary cirrhosis. J Hepatol 2008;49:881–883.
[137] Hohenester S, Wenniger LM, Paulusma CC, van Vliet SJ, Jefferson DM,
Elferink RP, et al. A biliary HCO3 umbrella constitutes a protective
mechanism against bile acid-induced injury in human cholangiocytes.
Hepatology 2012;55:173–183.
[138] Poupon R, Ping C, Chrétien Y, Corpechot C, Chazouillères O, Simon T, et al.
Genetic factors of susceptibility and of severity in primary biliary cirrhosis.
J Hepatol 2008;49:1038–1045.5 vol. 62 j 934–945
JOURNAL OF HEPATOLOGY
[139] Prieto J, Qian C, García N, Díez J, Medina JF. Abnormal expression of anion
exchanger genes in primary biliary cirrhosis. Gastroenterology
1993;105:572–578.
[140] Karlsen TH, Franke A, Melum E, Kaser A, Hov JR, Balschun T, et al. Genome-
wide association analysis in primary sclerosing cholangitis. Gastroenterol-
ogy 2010;138:1102–1111.
[141] Gotthardt D, Runz H, Keitel V, Fischer C, Flechtenmacher C, Wirtenberger
M, et al. A mutation in the canalicular phospholipid transporter gene,
ABCB4, is associated with cholestasis, ductopenia, and cirrhosis in adults.
Hepatology 2008;48:1157–1166.Journal of Hepatology 201[142] Laish I, Katz H, Sulayev Y, LibermanM, Naftali T, Benjaminov F, et al. Increased
TERC gene copy number and cells in senescence in primary sclerosing
cholangitis compared to colitis and control patients. Gene2013;529:245–249.
[143] Tkach M, Coria L, Rosemblit C, Rivas MA, Proietti CJ, Díaz Flaqué MC.
Targeting Stat3 induces senescence in tumor cells and elicits prophylactic
and therapeutic immune responses against breast cancer growth mediated
by NK cells and CD4+ T cells. J Immunol 2012;189:1162–1172.
[144] Wall M, Poortinga G, Stanley KL, Lindemann RK, Bots M, Chan CJ, et al. The
mTORC1 inhibitor everolimus prevents and treats El-Myc lymphoma by
restoring oncogene-induced senescence. Cancer Discov 2013;3:82–95.5 vol. 62 j 934–945 945
